drugset / Trial / NCT07446270
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Timeline
- Start
- 2026-03-03
- Primary completion
- 2027-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab β | Monoclonal antibody | 500 mg/m2 | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Tunlametinib | Small molecule | 6 mg | — |
| Subject | Tunlametinib | Small molecule | 9 mg | — |